Idiopathic Hypercalciuria & Nephrocalcinosis

📋 Key Information Summary

📋

Idiopathic hypercalciuria (IH) is defined as urinary calcium excretion >7.5 mmol/day (men) or >6.25 mmol/day (women) on a normal calcium diet, in the absence of identifiable secondary causes such as hyperparathyroidism, sarcoidosis, or malignancy.
IH is the most common metabolic abnormality detected in patients with calcium oxalate and calcium phosphate nephrolithiasis, present in approximately 40–60% of recurrent stone formers in Australia.
Three subtypes — absorptive (Type I and II), renal leak, and resorptive — differ in mechanism and have distinct management implications; absorptive Type I is the most prevalent.
Nephrocalcinosis (NC) denotes diffuse calcium salt deposition within the renal parenchyma, distinguished from nephrolithiasis by imaging characteristics on ultrasound or CT.
Medullary nephrocalcinosis accounts for >95% of cases and is most often associated with distal renal tubular acidosis, medullary sponge kidney, and IH; cortical NC is rare and suggests chronic glomerular disease, oxalosis, or cortical necrosis.
A properly collected 24-hour urine collection (ideally two separate collections) is the cornerstone of metabolic evaluation, measuring calcium, oxalate, citrate, urate, sodium, phosphate, volume, and creatinine (for adequacy check).
First-line lifestyle modification for all subtypes is a low-sodium diet (<6 g NaCl/day or <100 mmol Na/day), adequate fluid intake (>2.5 L/day), and normal calcium intake (1,000–1,200 mg/day) — restriction of dietary calcium paradoxically increases stone risk.
Thiazide diuretics (hydrochlorothiazide, indapamide, chlorthalidone) are the first-line pharmacotherapy for IH, reducing urinary calcium by 30–50% by enhancing proximal and distal tubular reabsorption.
Thiazides require concurrent potassium or potassium-sparing agent supplementation to prevent hypokalaemia, which itself reduces urinary citrate and promotes stones.
ATSI Australians have a rising prevalence of nephrolithiasis linked to dietary transition, remote healthcare access limitations, and higher rates of chronic kidney disease — all factors that alter management priorities.
Paediatric IH presenting with nephrocalcinosis requires specialist nephrology referral; thiazides may be used in children but monitoring of growth, electrolytes, and bone density is essential.
Patients with nephrocalcinosis warrant ongoing surveillance with renal ultrasound and annual estimated glomerular filtration rate (eGFR) to detect progressive parenchymal damage.

Introduction & Australian Epidemiology

Idiopathic hypercalciuria (IH) is the most common metabolic risk factor for calcium oxalate and calcium phosphate kidney stones. It is characterised by excessive urinary calcium excretion in the absence of identifiable secondary causes such as primary hyperparathyroidism, granulomatous disease, vitamin D excess, or malignancy. Nephrocalcinosis refers to diffuse deposition of calcium salts within the renal parenchyma, as distinct from nephrolithiasis, which describes discrete calculi within the collecting system.

Australian context: Kidney stones affect approximately 10–15% of the Australian population over a lifetime, with an age-standardised incidence of approximately 150 per 100,000 person-years. Calcium-containing stones (calcium oxalate and calcium phosphate) account for over 75% of all urinary calculi analysed in Australian laboratories. IH is identified in 40–60% of recurrent calcium stone formers referred to nephrology or urology clinics. Hospitalisation rates for urinary stone disease are highest in men aged 30–60 years and are increasing, particularly in tropical and subtropical regions of Queensland and the Northern Territory, where chronic dehydration contributes to supersaturation.

Nephrocalcinosis, though less common than nephrolithiasis, carries greater prognostic significance because parenchymal calcium deposition may lead to progressive tubulointerstitial fibrosis, impaired concentrating ability, and chronic kidney disease. Medullary nephrocalcinosis is far more common than cortical nephrocalcinosis and is associated with distal renal tubular acidosis (dRTA), medullary sponge kidney, and IH. The prevalence of nephrocalcinosis in paediatric populations is estimated at 0.5–1.7% by renal ultrasound screening.

This guideline reviews the classification, investigation, and evidence-based management of IH and nephrocalcinosis, with emphasis on Australian prescribing practices, Pharmaceutical Benefits Scheme (PBS) access, and Indigenous health considerations.

Pathophysiology

Calcium homoeostasis depends on the interplay of intestinal absorption, renal tubular reabsorption, and skeletal turnover. In IH, one or more of these pathways is dysregulated, leading to elevated filtered calcium load or impaired tubular recovery. The pathophysiology differs by subtype:

Intestinal hyperabsorption: Enhanced active transcellular calcium transport (mediated by TRPV6 channels and calbindin-D9k in duodenal enterocytes) increases fractional calcium absorption to >30% (normal ~20%). This elevates serum ionised calcium, suppresses parathyroid hormone (PTH), increases filtered calcium load, and may decrease proximal tubular phosphate reabsorption, causing mild hypophosphataemia and secondary 1,25-dihydroxyvitamin D elevation.
Renal calcium leak: A primary defect in distal tubular calcium reabsorption (TRPV5 channel dysfunction or claudin-14 dysregulation) leads to obligatory hypercalciuria. Compensatory secondary hyperparathyroidism maintains serum calcium but further increases bone turnover and urinary calcium.
Bone resorption (resorptive): Increased osteoclast-mediated calcium release from bone (distinct from hyperparathyroidism) contributes to the filtered load. This subtype overlaps with osteoporosis and may respond poorly to thiazides alone.

Regardless of the initiating mechanism, hypercalciuria increases urinary supersaturation with respect to calcium oxalate and calcium phosphate. Supersaturation drives nucleation, crystal growth, and aggregation — the prerequisites for stone formation. In nephrocalcinosis, crystals deposit within the tubular lumen and interstitium of the medulla, triggering an inflammatory cascade (NALP3 inflammasome activation, osteopontin and Tamm–Horsfall protein deposition) that culminates in fibrosis.

Types of Idiopathic Hypercalciuria

Although historically divided into absorptive, renal, and resorptive subtypes based on calcium-loading (fasting and calcium-supplemented) tests, most Australian centres now rely on 24-hour urine biochemistry and serum profiles for pragmatic classification.

Subtype	Mechanism	Serum Ca²⁺	Serum PTH	24h Urine Ca	Fasting Urine Ca	Prevalence
Absorptive Type I	Primary intestinal hyperabsorption	Normal–high	Low–normal	Markedly elevated	Normal	~50–60% of IH
Absorptive Type II	Intestinal hyperabsorption (diet-modifiable)	Normal	Normal	Elevated on normal diet; normalises on low-Ca diet	Normal	~15–20% of IH
Renal Leak	Primary renal tubular Ca²⁺ wasting	Normal–low	Elevated (secondary)	Elevated	Elevated	~15–20% of IH
Resorptive	Bone Ca²⁺ release (non-PTH)	Normal–high	Low–normal	Elevated	Elevated	~5–10% of IH

Absorptive Type I (Classic)

The most common and clinically significant subtype. Patients exhibit hypercalciuria on both normal and restricted calcium diets. Serum calcium is normal to high-normal; PTH is suppressed or low-normal. Fractional calcium absorption (if measured) exceeds 30%. These patients are typically resistant to dietary calcium restriction alone and usually require thiazide therapy.

Absorptive Type II (Diet-Modifiable)

Hypercalciuria is present on a normal calcium diet but normalises when dietary calcium is restricted to 400 mg/day. This form is managed primarily with dietary modification. Importantly, both Type I and Type II respond to reduced sodium intake, which lowers the filtered calcium load.

Renal Leak Hypercalciuria

A primary defect in renal tubular calcium reabsorption results in obligatory urinary calcium loss regardless of intake. Secondary hyperparathyroidism develops to maintain serum calcium but perpetuates the leak. Thiazides are particularly effective in this subtype because they directly enhance distal tubular calcium reabsorption.

Resorptive Hypercalciuria

Least common subtype; involves increased skeletal calcium mobilisation independent of PTH. Patients may have concurrent osteopaenia or osteoporosis. Investigation should exclude myeloma, immobilisation, thyrotoxicosis, and Paget disease. Treatment may require bone-protective agents (bisphosphonates) in addition to thiazides.

⚠️

Important: Always exclude secondary causes of hypercalciuria before labelling as "idiopathic." Primary hyperparathyroidism, sarcoidosis, vitamin D excess, immobilisation, malignancy, thyrotoxicosis, distal RTA, and medications (frusemide, corticosteroids) must be ruled out with serum calcium, PTH, 25-OH vitamin D, ACE level, TSH, and serum protein electrophoresis where indicated.

Investigations & 24-Hour Urine Collection

Metabolic evaluation is indicated for all patients with recurrent calcium stones (≥2 episodes), a single stone with high-risk features (solitary kidney, renal transplant, paediatric age), or nephrocalcinosis on imaging.

Baseline Serum Investigations

Essential

Corrected serum calcium

MBS item 66551 (if paired with PTH). Rule out hypercalcaemia/hyperparathyroidism.

Essential

Intact PTH

MBS item 66837. Differentiates absorptive (low/normal PTH) from renal leak (elevated PTH) subtypes.

Available

25-OH Vitamin D

MBS item 66831. Assess for vitamin D deficiency/excess; influences calcium absorption.

Available

1,25-(OH)₂ Vitamin D

MBS item 66832. May be elevated in absorptive IH or sarcoidosis.

Essential

Serum phosphate

May be low in absorptive IH (secondary phosphaturia).

Available

Serum urate, sodium, potassium, bicarbonate, creatinine, eGFR

Baseline renal function and acid–base status; hypokalaemia reduces urinary citrate.

Consider referral

Serum ACE level, serum protein electrophoresis

Exclude sarcoidosis and myeloma if clinically suspected.

24-Hour Urine Collection — The Cornerstone

Two separate 24-hour urine collections (ideally 4–6 weeks apart while the patient is on their usual diet) are recommended to improve reliability. Collections must be performed on an unrestricted diet and fluid intake.

Parameter	Normal Range	Relevance
Urinary calcium	<7.5 mmol/day (M)<br><6.25 mmol/day (F)	Diagnosis of IH; targets for therapy
Urinary oxalate	<0.5 mmol/day	Identifies concurrent hyperoxaluria
Urinary citrate	>2.5 mmol/day (M); >3.0 mmol/day (F)	Hypocitraturia promotes crystallisation
Urinary urate	<4.0 mmol/day	Urate promotes CaOx nucleation
Urinary sodium	<200 mmol/day (ideally <100)	High Na⁺ intake directly increases urinary Ca²⁺
Urinary phosphate	15–50 mmol/day	Phosphaturia in absorptive IH
Urinary volume	>2.5 L/day	Inadequate volume is the most common preventable risk factor
Urinary creatinine	≥8.8 mmol/day (M); ≥6.6 mmol/day (F)	Adequacy check — collection invalid if below threshold

✅

Collection tips: Ask the patient to discard the first morning void on Day 1 and collect all subsequent voids including the first morning void on Day 2. Acidify the collection vessel with dilute HCl (provided by the laboratory) to prevent calcium phosphate precipitation. Refrigerate the container during collection. Ensure the laboratory performs a creatinine adequacy check.

Stone Composition Analysis

Infrared spectroscopy or X-ray diffraction of passed or retrieved stones is essential. Australian pathology laboratories (e.g., Douglass Hanly Moir, Sullivan Nicolaides, Laverty) routinely perform stone analysis at no out-of-pocket cost through Medicare. Calcium oxalate monohydrate (whewellite), calcium oxalate dihydrate (weddellite), and calcium phosphate (apatite, brushite) have distinct risk profiles and therapeutic implications.

Imaging

Essential

Renal tract ultrasound

First-line imaging for nephrocalcinosis screening and stone surveillance. Non-ionising, suitable for paediatric and pregnant patients. Detects medullary hyperechogenicity and calyceal calculi.

Available

Low-dose non-contrast CT KUB (kidneys–ureters–bladder)

Gold standard for stone detection (sensitivity >95%). Not routine for nephrocalcinosis but useful for acute colic and surgical planning.

Consider referral

Medullary sponge kidney evaluation

Intravenous urography or CT urogram if nephrocalcinosis is bilateral and symmetrical. Medullary sponge kidney is a recognised cause of medullary nephrocalcinosis.

Clinical Presentation & Diagnostic Criteria

Idiopathic Hypercalciuria

Most patients with IH are asymptomatic until they develop their first kidney stone episode, typically presenting with:

Acute renal colic — severe, colicky flank pain radiating to the groin or labia/testis, often with nausea and haematuria
Microscopic or macroscopic haematuria
Recurrent urinary tract infections (staghorn calculi may predispose)
Incidental nephrocalcinosis or urolithiasis on imaging

In children, IH may present with haematuria (macroscopic or microscopic), dysuria, abdominal pain, or failure to thrive. Haematuria alone, without stone passage, may be the only manifestation in paediatric patients.

Diagnostic Criteria for IH

IH is a diagnosis of exclusion. The following criteria apply:

24-hour urinary calcium excretion above the upper limit of normal on at least two collections, on a normal diet (>7.5 mmol/day in men, >6.25 mmol/day in women, or >0.1 mmol/kg/day in children)
Normal serum calcium (corrected for albumin)
Absence of secondary causes (hyperparathyroidism, sarcoidosis, malignancy, vitamin D excess, thyrotoxicosis, immobilisation, distal RTA, frusemide use)

Nephrocalcinosis

Nephrocalcinosis is typically an imaging diagnosis. Patients may be asymptomatic or present with:

Polyuria and polydipsia (impaired urinary concentrating ability from tubulointerstitial injury)
Renal colic or stone passage
Haematuria
Progressive chronic kidney disease (in advanced cases)
Metabolic alkalosis or acidosis depending on the underlying aetiology

On ultrasound, nephrocalcinosis appears as hyperechoic medullary pyramids (medullary form) or increased cortical echogenicity (cortical form). Non-contrast CT demonstrates high-attenuation foci (>200 Hounsfield units) within the parenchyma.

Nephrocalcinosis: Medullary vs Cortical

Nephrocalcinosis is classified by the anatomical location of calcium deposition within the kidney. This distinction has important aetiological and prognostic implications.

Medullary Nephrocalcinosis (>95% of cases)

Calcium deposits are confined to the renal medulla — specifically the loops of Henle, vasa recta, and collecting ducts. The medullary interstitium is supersaturated due to countercurrent multiplication, acidic pH, and high local concentrations of calcium and phosphate.

Aetiology	Key Features
Distal renal tubular acidosis	Hyperchloremic metabolic acidosis, alkaline urine, hypercalciuria, hypocitraturia. Most common cause of medullary NC in children. Can be primary or secondary (Sjögren syndrome, SLE, amphotericin B).
Medullary sponge kidney	Cystic dilatation of medullary collecting ducts; bilateral in >70% of cases. Often presents in 30–50-year-olds with recurrent stones and NC. Diagnosed by IVU or CT urogram (brush-like blush of contrast in medullary pyramids).
Idiopathic hypercalciuria	The most common cause in adults. Medullary supersaturation drives intratubular crystal deposition.
Primary hyperparathyroidism	Hypercalcaemia + hypercalciuria → medullary calcium deposition. Important exclusion (treatable cause).
Papillary necrosis	Diabetes, NSAIDs, sickle cell disease/trait. Calcified necrotic papillae simulate NC on imaging.
Hyperoxaluria (primary or enteric)	Oxalate crystallisation in medulla. Enteric hyperoxaluria occurs after bariatric surgery, small bowel resection, or malabsorption states.
Bartter and Gitelman syndromes	Inherited tubulopathies. Bartter: hypokalaemic metabolic alkalosis, hypercalciuria, NC. Gitelman: hypocalciuria, hypomagnesaemia (typically no NC).
Prematurity	Up to 40% of preterm neonates develop transient medullary NC, usually resolving by age 2 years. Associated with frusemide therapy and low phosphate intake.

Cortical Nephrocalcinosis (Rare)

Calcium deposition within the renal cortex. This is a distinct entity with a more limited differential and generally worse prognosis, as it reflects irreversible cortical damage.

Acute cortical necrosis — post-partum haemorrhage, septic shock, snakebite, HELLP syndrome. Diffuse cortical calcification develops weeks to months after the acute insult.
Chronic glomerulonephritis — end-stage kidneys may develop cortical calcification.
Primary hyperoxaluria — Type 1 (AGXT deficiency) and Type 2 (GRHPR deficiency). Systemic oxalosis may deposit in cortex, bones, retina, myocardium, and vessels.
Alport syndrome and chronic allograft nephropathy

⚠️

Cortical nephrocalcinosis mandates urgent nephrology referral. It often indicates irreversible parenchymal damage and carries a high risk of progressive chronic kidney disease. Underlying aetiology must be identified and managed aggressively.

Risk Stratification

Not all patients with IH or a single stone event require the same intensity of investigation or treatment. Risk stratification guides the metabolic work-up and therapy intensity.

Low Risk

Single Stone, No Complications

First calcium stone in a patient without family history, solitary kidney, CKD, or nephrocalcinosis. Low recurrence risk (~15% at 5 years).

Management: General dietary advice, fluid intake >2.5 L/day, no routine 24-hour urine collection unless patient preference

Moderate Risk

Recurrent Stones or Risk Factors

≥2 stone episodes, family history of stones, bilateral stones, concurrent gout, obesity, bowel disease, or medullary sponge kidney. Recurrence risk ~40–50% at 5 years.

Management: Full metabolic evaluation (2× 24-hour urine + serum panel), targeted pharmacotherapy, dietary counselling by renal dietitian

High Risk

Nephrocalcinosis, Solitary Kidney, CKD, Paediatric

Nephrocalcinosis on imaging, solitary functioning kidney, eGFR <60, paediatric presentation, cystinuria, or primary hyperoxaluria. High recurrence and risk of CKD progression.

Management: Nephrology referral, full metabolic evaluation, pharmacotherapy, surveillance ultrasound every 6–12 months, annual eGFR

Management

Management of IH and nephrocalcinosis is multimodal, combining dietary modification (first-line for all patients), pharmacotherapy (for moderate-to-high-risk patients), and surveillance. The overarching goals are to reduce urinary calcium excretion, decrease urinary supersaturation, prevent further stone formation, and slow nephrocalcinosis progression.

Dietary & Lifestyle Modification

1

Fluid Intake

Target urine volume >2.5 L/day (≥3 L in hot climates such as Northern Australia). Distribute intake throughout the day, including before bed and during nocturnal voids. Water is preferred; avoid sugar-sweetened beverages. This single intervention reduces stone recurrence by approximately 50%.

2

Sodium Restriction

Limit dietary sodium to <100 mmol/day (<6 g NaCl/day). High sodium intake directly increases urinary calcium excretion by reducing proximal tubular sodium and calcium reabsorption. Reducing sodium by 100 mmol/day lowers urinary calcium by approximately 2.5 mmol/day. This is the single most effective dietary intervention for IH. Practical advice: avoid processed meats, canned foods, commercial sauces, and excessive table salt.

3

Normal Calcium Intake

Maintain dietary calcium at 1,000–1,200 mg/day (3 serves of dairy or equivalent). Do not restrict calcium. Low dietary calcium paradoxically increases intestinal oxalate absorption (by reducing intraluminary calcium–oxalate binding), increasing urinary oxalate and stone risk. Calcium supplements, if needed, should be taken with meals (not fasting).

4

Oxalate Moderation

Moderate intake of high-oxalate foods (spinach, rhubarb, beetroot, nuts, chocolate, tea) — complete avoidance is unnecessary and may reduce dietary variety.

5

Animal Protein Moderation

Limit animal protein to 1 g/kg/day. Excess purine intake increases uric acid excretion (which promotes calcium oxalate nucleation) and reduces urinary citrate.

6

Citrus Intake

Lemon juice (unsweetened) or citrate supplementation increases urinary citrate, an important inhibitor of calcium crystallisation. Target urinary citrate >3 mmol/day.

Pharmacotherapy — Thiazide Diuretics

Thiazide diuretics are the first-line pharmacotherapy for IH. They enhance calcium reabsorption in the distal convoluted tubule (via the NCC transporter and downstream effects on TRPV5 channels), reducing urinary calcium by 30–50%. Thiazides also reduce bone turnover and may improve bone mineral density.

💊

Hydrochlorothiazide

Dithiazide® · Moduretic® (with amiloride) · Thiazide diuretic

Adult dose 25–50 mg PO once daily (morning)

Paediatric dose 0.5–1 mg/kg/day PO, max 2 mg/kg/day, divided BD

Route Oral

Frequency Once daily (adults); BD (paediatric)

Duration Long-term (minimum 2–3 years; many patients require indefinite therapy)

Renal adjustment Efficacy reduced if eGFR <30 mL/min. Use lower doses.

Hepatic adjustment Caution in hepatic cirrhosis — may precipitate hepatic encephalopathy

PBS status ✔ PBS General Benefit

💊

Indapamide

Dapa-tabs® · Natrilix® · Thiazide-like diuretic

Adult dose 2.5 mg PO once daily (morning)

Paediatric dose Not routinely recommended in children <12 years

Route Oral

Frequency Once daily

Duration Long-term

Renal adjustment Avoid if eGFR <30 mL/min

PBS status ✔ PBS General Benefit

💊

Chlorthalidone

Hygroton® · Not PBS-listed · Thiazide-like diuretic

Adult dose 12.5–25 mg PO once daily

Note Longer half-life than hydrochlorothiazide; potentially more effective for nocturnal hypercalciuria. Not currently PBS-listed in Australia.

PBS status ✘ Not PBS

🚨

Hypokalaemia risk: All thiazides can cause hypokalaemia, which reduces urinary citrate excretion (citrate must enter cells via the Na⁺/K⁺-citrate cotransporter; hypokalaemia drives intracellular acidosis and citrate reabsorption). Always prescribe concurrent potassium supplementation or a potassium-sparing agent (see below).

Potassium-Sparing Agents & Supplements

💊

Amiloride

Amilzide® (with HCTZ) · Kaluril® · Potassium-sparing diuretic

Adult dose 5–10 mg PO once daily, often combined with hydrochlorothiazide

Role Prevents thiazide-induced hypokalaemia; also mildly reduces urinary calcium. Preferred K⁺-sparing agent for IH.

Renal adjustment Avoid if eGFR <30 mL/min or serum K⁺ >5.0 mmol/L

PBS status ✔ PBS General Benefit

💊

Potassium citrate

Urocit-K® · Not PBS · Citrate supplement

Adult dose 10–20 mmol PO BD–TDS (to target urinary citrate >3 mmol/day)

Role Increases urinary citrate (crystallisation inhibitor); alkalinises urine. Used when hypocitraturia persists despite thiazides and dietary measures.

Caution Avoid in severe renal impairment (risk of hyperkalaemia). Can cause GI upset.

PBS status ✘ Not PBS

Second-Line & Adjunctive Agents

💊

Allopurinol

Zyloprim® · Allosig® · Xanthine oxidase inhibitor

Adult dose 100–300 mg PO once daily

Indication Hyperuricosuria (>4 mmol/day) — uric acid promotes calcium oxalate heterogeneous nucleation

PBS status ✔ PBS General Benefit

💊

Neutral phosphate (sodium/potassium phosphate)

Various · Not PBS · Phosphate supplement

Adult dose 500 mg PO BD–TDS

Indication Hypophosphataemia with absorptive IH; reduces urinary calcium and increases urinary pyrophosphate (crystal inhibitor)

PBS status ✘ Not PBS

Management Algorithm Summary

All IH patients

Fluid >2.5 L/day + low sodium (<100 mmol Na/day) + normal calcium (1,000–1,200 mg/day) + moderate oxalate + moderate protein

Lifelong

Reassess 24h urine in 3 months

Persistent hypercalciuria or recurrent stones

Hydrochlorothiazide 25–50 mg daily + amiloride 5–10 mg daily

Minimum 2–3 years; often indefinite

Monitor K⁺, urate, lipids, glucose at 4 weeks then 6-monthly

Hypocitraturia (citrate <2.5 mmol/day)

Potassium citrate 10–20 mmol BD–TDS

Ongoing

Monitor serum K⁺; avoid if eGFR <30

Hyperuricosuria (>4 mmol/day)

Allopurinol 100–300 mg daily

Ongoing

HLA-B*5801 testing in ATSI patients before starting

Monitoring

Long-term monitoring is essential to assess treatment efficacy, detect adverse drug effects, and identify progressive nephrocalcinosis or CKD.

Baseline

Full metabolic panel (serum calcium, PTH, phosphate, urate, creatinine, eGFR, potassium, bicarbonate, FBC). Two 24-hour urine collections. Renal ultrasound. Stone analysis if available.

4 weeks

Serum potassium, sodium, creatinine, eGFR (post-thiazide initiation). Assess for hypokalaemia, hyponatraemia, hyperuricaemia. Symptom review.

3 months

Repeat 24-hour urine collection to assess response (target: urinary calcium <6 mmol/day, urine volume >2.5 L, urinary sodium <100 mmol/day). Serum electrolytes.

6 months

Serum electrolytes, eGFR, urate. Fasting glucose and lipid profile (thiazides may impair glucose tolerance and elevate LDL). Symptom and stone event review.

Annually

Repeat 24-hour urine (at least annually). Serum panel. Renal ultrasound (mandatory if nephrocalcinosis present — assess for progression). DEXA scan if concern for osteopaenia or in patients on long-term thiazides (therapeutic benefit expected).

ℹ️

Thiazide metabolic effects to monitor: Hypokalaemia (most common), hyponatraemia (especially in elderly), hyperuricaemia/gout, hyperglycaemia/new-onset diabetes, hyperlipidaemia, erectile dysfunction. Amiloride co-prescription mitigates hypokalaemia and may reduce other metabolic side effects.

Special Populations

🤰

Pregnancy

Thiazides

Category C — generally avoided in pregnancy, especially first trimester. Risk of neonatal thrombocytopenia, electrolyte disturbances. Use only if benefits clearly outweigh risks under specialist supervision.

Management

Dietary measures are the mainstay in pregnancy. Aggressive hydration. Monitor for pre-eclampsia (which may present with hypercalciuria). Renal ultrasound is safe; avoid CT.

👶

Paediatrics

Definition

IH in children: urinary calcium >0.1 mmol/kg/day (>4 mg/kg/day) on two collections.

Hydrochlorothiazide

0.5–1 mg/kg/day PO in divided doses. Monitor growth, serum electrolytes, and bone density. Specialist nephrology follow-up recommended.

Key considerations

Exclude secondary causes (Dent disease, Bartter syndrome, distal RTA, Williams syndrome). Nephrocalcinosis in children warrants thorough metabolic work-up and long-term nephrology follow-up.

👴

Elderly

Thiazides

Increased risk of hyponatraemia and falls. Start at lower doses (e.g., hydrochlorothiazide 12.5 mg). Monitor sodium at 1 and 4 weeks. Avoid thiazides if serum sodium <130 mmol/L.

Osteoporosis

Thiazides reduce urinary calcium loss and may improve bone density — beneficial in elderly patients with concurrent osteoporosis and IH. Consider DEXA monitoring.

🩺

Renal Impairment

Thiazides

Progressively less effective as eGFR declines below 50 mL/min; generally ineffective below 30 mL/min. Consider loop diuretics for fluid management (but these increase urinary calcium — not for stone prevention).

Monitoring

More frequent electrolyte monitoring in CKD stages 3b–5. Potassium citrate contraindicated if eGFR <30 due to hyperkalaemia risk.

🫁

Hepatic Impairment

Thiazides

Use with caution in hepatic cirrhosis — diuretic-induced hypokalaemia can precipitate hepatic encephalopathy. Monitor ammonia levels if symptomatic. Amiloride preferred over spironolactone for K⁺ sparing (less oestrogenic effect).

🛡️

Immunocompromised

Calcineurin inhibitors

Cyclosporin and tacrolimus cause hypercalciuria and nephrocalcinosis in transplant recipients. IH management must be coordinated with transplant team. Consider gout prophylaxis (allopurinol interaction with azathioprine).

HIV

Indinavir (older protease inhibitor) caused crystalluria; tenofovir may cause proximal tubulopathy with phosphaturia and secondary hypercalciuria.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

Urinary stone disease is increasingly recognised in ATSI communities, particularly in remote and very remote areas of the Northern Territory, Western Australia, and Queensland. AIHW data suggest rising hospitalisation rates for kidney stones among ATSI Australians, driven by dietary transition (high sodium processed foods), inadequate hydration, and limited access to preventive healthcare. Nephrocalcinosis in ATSI children may be associated with prematurity, low birth weight, and recurrent urinary tract infections.

Barriers to care

Geographic remoteness limits access to nephrology and urology specialists, diagnostic imaging, and 24-hour urine collection facilities. Cultural and language barriers may impede dietary counselling. Competing health priorities (diabetes, cardiovascular disease, chronic kidney disease) mean that metabolic stone evaluation may be deprioritised. Intermittent community pharmacy stock-outs affect medication continuity.

CKD intersection

ATSI Australians have 2–3 times the rate of CKD compared to non-Indigenous Australians. IH and nephrocalcinosis can contribute to CKD progression, and CKD itself modifies treatment options (thiazide efficacy, potassium citrate safety). eGFR monitoring is essential and should be incorporated into existing chronic disease management plans (715 Health Checks).

Medication considerations

Before initiating allopurinol in ATSI patients, HLA-B*5801 genotyping is recommended (higher prevalence in some Indigenous populations, shared ancestry risk with Southeast Asian populations). Ensure thiazide and amiloride availability through Remote Area Aboriginal Health Services (RAAHS) and Aboriginal Medical Services (AMS). PBS co-payments may be reduced through Closing the Gap PBS co-payment measure.

Cultural safety

Engage Aboriginal Health Workers and Liaison Officers in dietary education. Use culturally appropriate resources (e.g., Australian Indigenous HealthInfoNet). Respect Sorry Business and community obligations that may affect appointment attendance. Telehealth nephrology consultations can bridge specialist access gaps — support through MBS items 91822 and 91823.

Dietary advice

Practical low-sodium dietary advice must account for food availability and cost in remote communities, where fresh produce is expensive and shelf-stable foods are high in sodium. Collaborate with community nutritionists and use the Australian Dietary Guidelines adapted for remote ATSI communities. Bush tucker and traditional foods may be lower in sodium than processed alternatives.

📚 References

1. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954–963.
2. Gambaro G, Croppi E, Coe F, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016;29(6):715–734.
3. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med. 2004;164(8):885–891.
4. Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009;56(1):72–80.
5. Australian Institute of Health and Welfare (AIHW). Kidney disease in Australia. Cat. no. PHE 229. Canberra: AIHW; 2021.
6. The Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 10th edn. East Melbourne: RACGP; 2024.
7. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights from calcium crystallisation in the kidney. Clin Sci (Lond). 2020;134(12):1489–1506.
8. Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med. 2003;115(1):26–32.
9. Escribano J, Balaguer A, Pagone F, Roqué i Figuls M, Feliu A. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev. 2009;(1):CD004754.
10. National Health and Medical Research Council (NHMRC). Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC; 2020.
document.querySelectorAll('.topic-toc a[href^="#"]').forEach(o=>{o.addEventListener("click",i=>{const t=o.getAttribute("href")||"",e=document.querySelector(t);if(!e)return;i.preventDefault();const n=e.getBoundingClientRect().top+window.scrollY-70;window.scrollTo({top:n,behavior:"smooth"}),history.replaceState(null,"",t)})});const r=new Map;document.querySelectorAll(".topic-toc a").forEach(o=>{const i=o.getAttribute("href")?.slice(1);i&&r.set(i,o)});if(r.size>0&&"IntersectionObserver"in window){const o=new IntersectionObserver(i=>{let t=null;for(const e of i)if(e.isIntersecting){t=e.target.id;break}t&&r.forEach((e,n)=>e.classList.toggle("active",n===t))},{rootMargin:"-80px 0px -40% 0px",threshold:0});r.forEach((i,t)=>{const e=document.getElementById(t);e&&o.observe(e)})}window.matchMedia("(max-width: 900px)").matches&&document.querySelector(".topic-rail-collapsible")?.removeAttribute("open");const c=document.querySelector(".topic-rail-details");function s(){c&&(window.matchMedia("(max-width: 900px)").matches?c.open=!1:c.open=!0)}s();let l;window.addEventListener("resize",()=>{clearTimeout(l),l=window.setTimeout(s,120)});